Flamingo Therapeutics appoints new board member and more digital health hires

RNA-focused digital therapeutics company Flamingo Therapeutics added a new member to its board of directors, Dr. Ezra Cohen. 

Flamingo produces RNA therapies for oncology and is backed by investors such as Andera Partners, Bpifrance Large Venture, Perceptive Advisors, Sphera and VIB. 

Dr. Cohen has a history in the development of pharmaceuticals, especially head and neck cancers.  

“The science and team at Flamingo are very impressive, and I am excited to join the board following the recent initiation of several important oncology clinical studies. I believe that Flamingo is uniquely positioned to improve the head and neck treatment landscape with its RNA-targeting approach, and I look forward to working with the team to deliver new therapeutic options for patients,” Dr. Cohen said in a statement.

Life sciences software company Synthace announced the appointment of Willem Baralt as its new chairman of the board. Baralt joined the company in February. 

Synthace supports R&D scientists through automation across various stages, including experimental design, simulations and the creation of comprehensive digital records.

Baralt has served on several boards of healthcare and charitable organizations. Most recently, he served at portable dialysis machine maker Quanta Dialysis Technologies, which secured $245 million in Series D funding in 2021. 

“I am truly honored to join the Synthace team at this point in time as it is looking to transform the life sciences R&D landscape.  With its digital experimentation platform, Synthace empowers scientists to design and execute experiments that were previously impossible. Synthace’s technology is key to enabling the R&D lab of the future, allowing its customers to make new therapies while achieving radical time and cost savings,” Mr. Baralt said in a statement.